Independent opinions of independent directors on the self-evaluation report of internal control in 2021
In accordance with the Listing Rules of Shenzhen Stock Exchange, the governance standards of listed companies, the guiding opinions on the establishment of independent director system in listed companies, the articles of association, the independent director system and other relevant regulations and systems, as independent directors of Berry Genomics Co.Ltd(000710) (hereinafter referred to as “the company”), we hereby express the following independent opinions on the self-evaluation report on internal control of the company in 2021:
During the reporting period, the company continuously improved its internal control system in strict accordance with the company law, securities law, guidelines on internal control of listed companies and relevant laws and regulations. The 2021 annual internal control self-evaluation report issued by the company is compiled and reported in accordance with the rules for the preparation and reporting of information disclosure of companies offering securities to the public No. 21 – General Provisions on annual internal control evaluation report, which truly and objectively reflects the actual situation of the construction of the company’s current internal control system, the implementation and supervision of the internal control system.
In the future reporting period, the company will further strengthen the standardization of internal control and continue to establish the formulation and effective implementation of internal control system.
We believe that the company’s internal control system and relevant systems at this stage can meet the requirements of the company’s management and the needs of development; Be able to guarantee the compliance operation of the company’s businesses and the control of the company’s business risks; Be able to treat all investors openly, fairly and fairly, and effectively protect the interests of the company and investors. There is no violation of the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of listed companies on the main board and various internal control systems of the company.
Independent directors: Wang Xiuping, Li Guangchao, Wang Sijia April 14, 2022
